Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)

Overview of attention for article published in Journal of Neuroimmune Pharmacology, November 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#46 of 583)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 9 X users

Citations

dimensions_citation: 36 Dimensions

Readers on

mendeley: 77 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 1 news story.

Rituxan Has Some Benefits in MS, Neuromyelitis Optica

MedPage Today, 30 Nov 2015

Action Points Off-label use of rituximab (Rituxan) was relatively effective and well tolerated in patients with multiple…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.